Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 17/20 | 0.39 |
| ▸ | CD99 | P14209 | 1/20 | 0.38 |
| ▸ | CD79B | P40259 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20347383 | 0.90 | NT5E (0.45) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347234 | 0.87 | NT5E (0.46) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347237 | 0.85 | LMNA (0.44) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347235 | 0.85 | LMNA (0.44) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347238 | 0.84 | NT5E (0.40) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20305246 | 0.81 | LMNA (0.49) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL19948520 | 0.80 | NT5E (0.55) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347385 | 0.80 | ALDH1A1 (0.37) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347236 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNATP53MAPTTDP1 | |
| SCHEMBL20347375 | 0.78 | NT5E (0.45) | ALDH1A1LMNATP53MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | ALDH1A1 527/4885LMNA 2684/4885TP53 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.